Unresectable Stage III non-small cell lung cancer without progression research hub

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy

This study compares a new medicine, pumitamig, with an existing one, durvalumab, for people with a type of lung cancer that hasn't spread beyond the chest and hasn't grown after initial treatment. Researchers want to see which medicine is better at stopping the cancer from growing.